| 生物活性 |
Lifastuzumab vedotin (RG-7599; DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research.
|
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAS号 |
1401812-88-1
|
||||||||||||
| 中文名称 |
Anti-NaPi3b vedotin
|
||||||||||||
| 运输条件 |
Shipping with dry ice.
|
||||||||||||
| 储存方式 |
|
纯度： 99%
咨询热线：
400-881-9290
Data Sheet
